Characteristics of 12 (among 996) patients who died during or within the 12 weeks following direct-acting antivirals (DAAs) therapy for HCV chronic infection
| Patient | Age at death | Sex | Fibrosis stage | Regimen (weeks) | Timing of death | Cause of death |
|---|---|---|---|---|---|---|
| 1 | 82 | M | Cirrhosis child C10 | SOF+SMV (10) | W10 | HCC |
| 2 | 76 | F | Cirrhosis child B7 | SOF+DCV (12) | W12 | Encephalopathy |
| 3 | 65 | M | F2+ | SOF+SMV (12) | W12 | Sudden death |
| 4 | 55 | M | Cirrhosis child A | SOF+LDV+RBV (8) | W8 | Sudden death |
| 5 | 68 | F | Cirrhosis child C | SOF+DCV (20) | FU W4 | Encephalopathy, sepsis and metastatic breast cancer |
| 6 | 58 | F | Cirrhosis child B | 2D+RBV (6) | W6 | Liver failure |
| 7 | 69 | M | Cirrhosis child A | SOF+DCV (24) | FU W4 | Sepsis |
| 8 | 56 | M | Cirrhosis child B7 | SOF+DCV (24) | FU W10 | Haemorrhagic stroke |
| 9 | 67 | M | Cirrhosis child C10 | SOF+TLV (12) | FU W11 | Haemorrhagic stroke |
| 10 | 68 | M | F3 | SOF+LDV (5) | W5 | Sudden death |
| 11 | 71 | F | F3 | SOF+LDV (12) | FU W7 | Sepsis with toxic medullar aplasia |
| 12 | 71 | F | F1/cryoglobulinaemia | GZP+ELV (12) | FU W12 | Peritonitis on diverticulitis |
2D, ombitasvir/paritaprevir/ritonavir; DCV, daclatasvir; ELV, elbasvir; FU, follow-up; GZP, grazoprevir; HCC, hepatocellular carcinoma; LDV, ledipasvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; TLV, telaprevir; W, week.